These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36288392)

  • 21. Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors.
    Ikeda D; Chi S; Uchiyama S; Nakamura H; Guo YM; Yamauchi N; Yuda J; Minami Y
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High-risk acute myeloid leukemia with DEK-NUP214 rearrangement and eyelid infiltration: a case report].
    Li XZ; Huang R; Gao TQ; Xie XW; Zhou YQ; Zeng QL; Liu JD; Gu XK; Liu ZH
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):512. PubMed ID: 38964929
    [No Abstract]   [Full Text] [Related]  

  • 23. t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities.
    Baldazzi C; Luatti S; Marzocchi G; Grassi A; Cavo M; Testoni N
    Cancer Genet; 2022 Apr; 262-263():35-39. PubMed ID: 34979355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel variant translocation (1;9)(p22;q34) resulting in a DEK/NUP214 fusion gene in a patient with acute myeloid leukemia: A case report.
    Hao Q; Zhang Q; Li C; Wei S; Li Q; Song Y; Mi Y
    Oncol Lett; 2017 Dec; 14(6):7021-7024. PubMed ID: 29344131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NUP214 in Leukemia: It's More than Transport.
    Mendes A; Fahrenkrog B
    Cells; 2019 Jan; 8(1):. PubMed ID: 30669574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology.
    Kuo YJ; Lewis JS; Zhai C; Chen YA; Chernock RD; Hsieh MS; Lan MY; Lee CK; Weinreb I; Hang JF
    Mod Pathol; 2021 Oct; 34(10):1820-1830. PubMed ID: 34108636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear DEK preserves hematopoietic stem cells potential via NCoR1/HDAC3-Akt1/2-mTOR axis.
    Chen Z; Huo D; Li L; Liu Z; Li Z; Xu S; Huang Y; Wu W; Zhou C; Liu Y; Kuang M; Wu F; Li H; Qian P; Song G; Wu X; Chen J; Hou Y
    J Exp Med; 2021 May; 218(5):. PubMed ID: 33755722
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Choi YJ; Min YK; Lee ST; Choi JR; Shin S
    Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report.
    Zhang X; Zhang X
    Ann Palliat Med; 2021 Apr; 10(4):4955-4958. PubMed ID: 33832283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
    Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
    PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a potential topoisomerase II "hotspot" DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms.
    Piredda ML; Catalano G; Ciardi C; Divona M; Cicconi L; Panetta P; Curzi P; Garza E; Martínez-Losada C; Postorino M; Lo-Coco F; Noguera NI
    Ann Hematol; 2017 Jan; 96(1):155-157. PubMed ID: 27734129
    [No Abstract]   [Full Text] [Related]  

  • 32. Imatinib therapy in acute myeloid leukemia with DEK-NUP214 and FIP1L1-PDGFRA rearrangement: A case report.
    Yang Y; Lin H; Du Z; Hu R; Tang Y; Liang X; Sun J; Tan Y
    Oncol Lett; 2020 May; 19(5):3587-3592. PubMed ID: 32269633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines.
    Quentmeier H; Schneider B; Röhrs S; Romani J; Zaborski M; Macleod RA; Drexler HG
    J Hematol Oncol; 2009 Jan; 2():3. PubMed ID: 19166587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NUP214-RAC1 and RAC1-COL12A1 Fusion in Complex Variant Translocations Involving Chromosomes 6, 7 and 9 in an Acute Myeloid Leukemia Case with DEK-NUP214.
    Abe A; Yamamoto Y; Iba S; Okamoto A; Tokuda M; Inaguma Y; Yanada M; Morishima S; Kanie T; Tsuzuki M; Akatsuka Y; Mizuta S; Okamoto M; Kameyama T; Mayeda A; Emi N
    Cytogenet Genome Res; 2015; 146(4):279-84. PubMed ID: 26517539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
    Sandén C; Järvstråt L; Lennartsson A; Brattås PL; Nilsson B; Gullberg U
    Mol Cancer; 2014 Sep; 13():215. PubMed ID: 25216995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nuclear DEK interactome supports multi-functionality.
    Smith EA; Krumpelbeck EF; Jegga AG; Prell M; Matrka MM; Kappes F; Greis KD; Ali AM; Meetei AR; Wells SI
    Proteins; 2018 Jan; 86(1):88-97. PubMed ID: 29082557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation.
    Oancea C; Rüster B; Henschler R; Puccetti E; Ruthardt M
    Leukemia; 2010 Nov; 24(11):1910-9. PubMed ID: 20827285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin.
    Guo H; Prell M; Königs H; Xu N; Waldmann T; Hermans-Sachweh B; Ferrando-May E; Lüscher B; Kappes F
    FEBS Lett; 2021 May; 595(10):1438-1453. PubMed ID: 33686684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Complexity of DEK Signaling in Cancer Progression.
    Teng Y; Lang L; Jauregui CE
    Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.